Thank you for donating!

You can donate using the following services.

UK Specialist Centres

Specialist care centres can provide comprehensive, integrated, multidisciplinary care for patients, as well as information and support for family members. They aim to incorporate networks of all relevant medical disciplines within the core team.  They have effective links with national networks of testing laboratories and other care centres at a national and international level.

Specialist nurses play a vital role in the day-to-day running of clinics and deal with many of the familial aspects of work with patients and family members. Physical therapists, speech therapists, occupational therapists and disease counsellors should also all be involved in supportive care for patients.

Everyone affected by Niemann-Pick disease in England is entitled to receive their clinical care at a Specialist Centre: 

Adult Niemann-Pick Disease Patient Centres:

Paediatric Niemann-Pick Disease Patient Centres:

Scotland, Wales and Northern Ireland:

Arrangements are in place for patients from Scotland, Wales and Northern Ireland to be seen within the designated centres in England for diagnosis and clinical management.  Decisions on funding treatment/access remain with the patient’s local health authority:

For further information visit the NHS Specialised Service Website.

specialist

Latest news

31.10.19

Cyclo Therapeutics Announces Its Publication of the Most Extensive Set of Case Study Reports To-date on Expanded Access Use of Hydroxypropyl Beta Cyclodextrin in Niemann-Pick Disease Type C

Publication describes favorable safety profile and efficacy in neurologic and other disease features in individual NPC patients following intravenous administration of drug...

Read more

22.10.19

Cyclo Therapeutics Announces Completion of Enrollment in its Phase I Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

GAINESVILLE, FL – (Businesswire) – October 22, 2019 – Cyclo Therapeutics, Inc. (OTCQB: CTDH), formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that it has completed patient enrollment in its Phase I trial to evaluate the safety and tolerability of Trappsol® Cyclo™ administered intravenously to Niemann-Pick Disease Type C (NPC) patients.

Read more
View all news Subscribe